Adult: Usual dose: 10-20 mg once daily. Child: >12 years Same as adult dose.
Oral Chronic idiopathic urticaria
Adult: 10 mg once daily. Child: >12 years Same as adult dose.
Severe: Max: 10 mg daily.
May be taken with or without food.
Patient with cardiac risks (e.g. long QT syndrome, hypokalaemia, treatment with agents known to increase QT interval). Concomitant use with CYP3A4 inhibitors. Severe hepatic impairment. Children. Pregnancy and lactation.
Cardiac disorders: Rarely, palpitation, tachycardia. Gastrointestinal disorders: Dry mouth. Rarely, dysgeusia, abdominal pain, nausea, dyspepsia, vomiting. General disorders and administration site conditions: Asthenia. Hepatobiliary disorders: Rarely, hepatitis, cholestasis. Immune system disorders: Rarely, hypersensitivity reactions (e.g. angioedema, anaphylaxis). Investigations: Rarely, abnormal LFTs. Nervous system disorders: Headache, drowsiness. Rarely, dizziness, hypoesthesia. Psychiatric disorders: Rarely, nervousness, insomnia. Reproductive system and breast disorders: Rarely, menstrual disorders. Respiratory, thoracic and mediastinal disorders: Pharyngitis, sinusitis, epistaxis.
Patient Counseling Information
This drug may cause drowsiness or sometimes dizziness; if affected, do not drive or operate machinery.
Increased plasma levels and risk of QTc interval prolongation with ketoconazole, itraconazole and erythromycin. Plasma concentrations and antihistamine effects may be decreased by rifampicin.
Plasma levels of carebastine may be increased by 1.5-2 fold with food.
May interfere with allergy skin test results.
Description: Ebastine, a piperidine derivative, is a long-acting, non-sedating antihistamine that selectively binds to histamine H1 receptors to inhibit the effects of histamines. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Food may increase the plasma levels of carebastine (active metabolite). Time to peak plasma concentration: Approx 2-4 hours (carebastine). Distribution: Plasma protein binding: >95%. Metabolism: Almost completely metabolised primarily by CYP3A4 isoenzyme into carebastine; undergoes extensive hepatic and intestinal first-pass metabolism. Excretion: Via urine (66%, primarily as conjugated metabolites). Elimination half-life: 15-19 hours (carebastine).